Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

655 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase III study with FOLFIRI + cetuximab versus FOLFIRI + cetuximab followed by cetuximab alone in RAS and BRAF WT mCRC.
Pinto C, Normanno N, Orlandi A, Fenizia F, Damato A, Maiello E, Tamburini E, Di Costanzo F, Tonini G, Bilancia D, Corsi D, Pisconti S, Ferrau F, Gori S, Daniele B, Zaniboni A, Soto Parra H, Frassinetti GL, Iaffaioli RV, Cassata A, Zampino MG, Repetto L, Calegari MA, Barone C; all the investigators of ERMES study group.. Pinto C, et al. Among authors: damato a. Future Oncol. 2018 Jun;14(14):1339-1346. doi: 10.2217/fon-2017-0592. Epub 2018 May 30. Future Oncol. 2018. PMID: 29846100 Clinical Trial.
Phase II Study of Preoperative Treatment with External Radiotherapy Plus Panitumumab in Low-Risk, Locally Advanced Rectal Cancer (RaP Study/STAR-03).
Pinto C, Di Bisceglie M, Di Fabio F, Bochicchio A, Latiano T, Cordio S, Rosati G, Aschele C, Marino A, Bergamo F, Bustreo S, Frassineti L, Ciardiello F, Damato A, Giaquinta S, Baldari D, Boni L. Pinto C, et al. Among authors: damato a. Oncologist. 2018 Aug;23(8):912-918. doi: 10.1634/theoncologist.2017-0484. Epub 2018 Mar 9. Oncologist. 2018. PMID: 29523646 Free PMC article. Clinical Trial.
Phase II study on first-line treatment of NIVolumab in combination with folfoxiri/bevacizumab in patients with Advanced COloRectal cancer RAS or BRAF mutated - NIVACOR trial (GOIRC-03-2018).
Damato A, Iachetta F, Antonuzzo L, Nasti G, Bergamo F, Bordonaro R, Maiello E, Zaniboni A, Tonini G, Romagnani A, Berselli A, Normanno N, Pinto C. Damato A, et al. BMC Cancer. 2020 Aug 31;20(1):822. doi: 10.1186/s12885-020-07268-4. BMC Cancer. 2020. PMID: 32867715 Free PMC article.
655 results